The company’s transition into a clinical-stage entity is overseen by newly appointed CEO Katie MacFarlane, a veteran with over 35 years of experience in pharmaceutical development. Arkayli is now initiating a Phase 1b trial to evaluate the safety of ARK001, which is designed to be applied directly to infant skin during the critical early months of tumor proliferation. By shifting the treatment paradigm away from systemic options, the firm hopes to reduce the risk of permanent scarring and psychosocial distress associated with untreated hemangiomas on the face and neck.

To sustain this momentum, Arkayli has launched a Series A financing round. The capital will support the upcoming trial and further pipeline development. Chairman Thomas Rossi noted that the team has finalized the preclinical research and manufacturing preparations required to move the asset into human testing. Currently, most infants wait over five months for specialist intervention, a gap the company intends to close by equipping pediatricians and dermatologists with a more accessible, topical therapeutic option.